Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech disclosure the size of a clinical dossier is no small task. PTC Therapeutics’ filings stretch across hundreds of pages packed with trial data, royalty terms, and orphan-drug exclusivity clauses—details most investors cannot scan overnight. This page delivers PTC Therapeutics SEC filings explained simply so you can move from raw data to clear insight.
Stock Titan’s AI reads every submission the moment it hits EDGAR, translating jargon into plain language summaries. Whether you need a PTC Therapeutics quarterly earnings report 10-Q filing to track R&D burn, or an 8-K describing an FDA decision—PTC Therapeutics 8-K material events explained—our platform highlights the numbers and milestones that move the share price.
Key documents covered in real time:
- Form 4 – PTC Therapeutics insider trading Form 4 transactions and PTC Therapeutics Form 4 insider transactions real-time show exactly when executives buy or sell shares.
- 10-Q – AI pinpoints quarter-over-quarter pipeline spend, giving you fast PTC Therapeutics earnings report filing analysis.
- 10-K – Get the PTC Therapeutics annual report 10-K simplified, including cash-runway tables and risk-factor changes.
- DEF 14A – Review the PTC Therapeutics proxy statement executive compensation to evaluate incentives behind strategic decisions.
Still unsure where a specific disclosure lives? Type a plain question—“understanding PTC Therapeutics SEC documents with AI”—and let our engine surface the exact section, be it gene-therapy manufacturing obligations or collaboration milestones. Monitor PTC Therapeutics executive stock transactions Form 4, compare trial updates across periods, and make informed calls without wading through chemistry appendices. Complex science, distilled to actionable data—updated the second PTC files.
PTC Therapeutics director reports stock option exercise and share acquisition. A board member exercised a stock option on 12/16/2025 to acquire 24,000 shares of PTC Therapeutics common stock at an exercise price of $30.86 per share. The transaction is coded "M," indicating an option exercise. Following this transaction, the director beneficially owns 155,266 shares of common stock held directly. The exercised option covered 24,000 shares, was noted as currently exercisable, and carries an expiration date of 01/03/2026.
PTC Therapeutics, Inc. director reports option exercise and share sale. On 12/03/2025, the director exercised a stock option for 733 shares of common stock at $46.54 per share and then sold 733 common shares at $78.62 per share. After these transactions, the director directly beneficially owned 6,666 shares of PTC Therapeutics common stock.
The stock option exercised on that date had a conversion price of $46.54 and relates to 733 underlying common shares. Following the transaction, the director held 734 derivative securities (stock options) expiring on 01/02/2035. The filing notes that the transaction was effected under a written Rule 10b5-1 trading plan adopted on March 4, 2025, which is designed to standardize trading and help address trading‑window and insider‑trading concerns.
PTC Therapeutics, Inc. (PTCT) reported insider activity by its Chief Technical Operations Officer. On 11/24/2025, the executive exercised several stock options to buy common stock at exercise prices of $18.01 and $33.02 per share and, on the same date, sold corresponding shares of common stock in multiple transactions at weighted average prices around $80 per share, with specific ranges disclosed for each sale.
The transactions were carried out under a written Rule 10b5-1 trading plan adopted on December 10, 2024, which is intended to provide an affirmative defense for pre-planned trades. Following the reported transactions, the executive beneficially owned 100,625 shares of PTCT common stock directly and an additional 6,179 shares indirectly through a spouse. Certain stock options reported in the filing are noted as currently exercisable, with stated expiration dates in 2028 and 2029.
PTC Therapeutics (PTCT) director reports option exercises and stock sales. A board member exercised stock options on 11/24/2025 and 11/25/2025 at exercise prices of $11.23 and $18.01 per share, converting options into common stock. On the same dates, the director sold shares in multiple transactions at weighted average prices generally between the low $80 and mid $80 per share. After these transactions, the director directly owned 17,451 shares of PTC Therapeutics common stock. The filing states that the trades were carried out under a written Rule 10b5-1 trading plan adopted on March 12, 2025.
PTC Therapeutics director reports stock option exercise and sale. A board member of PTC Therapeutics, Inc. (PTCT) exercised stock options for 10,000 shares of common stock at an exercise price of $51.16 per share on 11/21/2025. On the same day, the director sold 10,000 shares of common stock at a price of $79.50 per share. After these transactions, the director beneficially owned 6,666 shares of PTCT common stock directly. The option exercise was reported as a stock option (right to buy) that was already exercisable and carries an expiration date of 01/28/2030. The filing notes that the transactions were carried out under a pre‑established Rule 10b5‑1 trading plan adopted on March 4, 2025, which is designed to allow trading under predetermined conditions.
PTC Therapeutics director reports charitable stock gift
A director of PTC Therapeutics, Inc. (PTCT) reported a bona fide gift of 867 shares of the company’s common stock on 11/20/2025. The transaction was coded as a gift and priced at $0, reflecting that no sale proceeds were received. After this transaction, the reporting person beneficially owns 8,000 shares of PTC Therapeutics common stock in direct ownership. The filing is made on Form 4 for a single reporting person and indicates the shares were donated to a charitable organization.
PTC Therapeutics executive reports option exercise and share sales
The Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (PTCT) reported transactions dated 11/17/2025. The officer exercised a stock option for 2,812 shares of common stock at an exercise price of $25.69 per share, then sold 1,843 shares at a weighted average price of $75.64, 777 shares at $76.53, and 192 shares at $77.18, all under a Rule 10b5-1 trading plan adopted on December 5, 2024.
After these transactions, the officer beneficially owned 103,901 shares of common stock directly and 25,314 stock options with an exercise price of $25.69 expiring on 02/14/2034. The reported option grant was made on February 15, 2024 and vests over four years, with 25% vesting on February 15, 2025 and 6.25% of the original grant vesting at the end of each three-month period thereafter.
PTC Therapeutics (PTCT) filed its Q3 2025 10‑Q, reporting a return to profitability for the quarter and sharply higher year‑to‑date results. Q3 revenue was $211.0 million (vs. $196.8 million a year ago), and net income was $15.9 million (vs. a $106.7 million loss). Diluted EPS was $0.20.
For the first nine months, revenue reached $1.566 billion (vs. $593.6 million), driven by $998.4 million of collaboration and license revenue tied to the Novartis votoplam agreement, with net income of $817.6 million. Cash and cash equivalents were $672.6 million and marketable securities $1.015 billion. The stockholders’ deficit narrowed to $(155.8) million from $(1.10) billion at year‑end.
Product and pipeline updates include FDA approval of Sephience for PKU in July 2025 (and EC authorization in June 2025), EC non‑renewal of Translarna in March 2025 with certain EU country exceptions, and FDA acceptance of the resubmitted Translarna NDA in October 2024. The FDA approved the AADC gene therapy in the U.S. in November 2024 (marketed as Kebilidi). The FDA issued a complete response letter for vatiquinone in August 2025. The Novartis votoplam deal closed in January 2025 with a $1.0 billion upfront payment.
PTC Therapeutics filed an 8-K announcing financial results for the quarter ended September 30, 2025. The full details are provided in a press release furnished as Exhibit 99.1.
The company will host a conference call on November 4, 2025 at 4:30 p.m. Eastern to review the results and other updates. Items 2.02 and 7.01, and Exhibit 99.1, are furnished and not deemed filed under Section 18 of the Exchange Act.
PTC Therapeutics (PTCT) director reported Rule 10b5-1 trades. On 10/30/2025, the insider exercised 12,000 stock options at $38.1 per share and sold 12,000 common shares at $69.5. The filing also lists a separate sale of 3,666 shares at $69.5. After these transactions, the insider reported 6,666 shares held directly.
The trades were effected pursuant to a written Rule 10b5-1 plan adopted on March 4, 2025. The exercised options were currently exercisable and carry an expiration date of January 6, 2032.
FAQ
What is the current stock price of Ptc Therapeutics (PTCT)?
What is the market cap of Ptc Therapeutics (PTCT)?
